Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive, catheter-based procedure designed to treat severe aortic stenosis, a condition in which the aortic valve becomes narrowed and restricts blood flow from the heart to the rest of the body. This narrowing increases the workload on the left ventricle and can lead to symptoms such as shortness of breath, chest pain, fatigue, dizziness, and syncope. Without appropriate treatment, severe symptomatic aortic stenosis can progress to heart failure and other life-threatening complications.

​

TAVR provides an alternative to traditional surgical aortic valve replacement (SAVR) by allowing a new bioprosthetic valve to be implanted without the need for open-heart surgery. The primary goal of TAVR is to relieve aortic valve obstruction, improve cardiac function, reduce symptoms, and enhance the patient’s quality of life. Patient selection involves a comprehensive evaluation by a multidisciplinary Heart Team, including assessment of valve anatomy, vascular access, procedural risks, and overall clinical condition.

​

TAVR has become a cornerstone of modern structural heart interventions, offering eligible patients with severe aortic stenosis an effective, less invasive treatment option that can improve symptoms, functional capacity, and long-term clinical outcomes.